Comparative study of Botox injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage.
OBJECTIVE
To compare morphometric data of the eyelid fissure and the levator muscle function (LF) before and up to 6 months after transcutaneous injection with five units of Botox in patients with upper lid retraction (ULR) from congestive or fibrotic thyroid eye disease (TED).


METHODS
Twenty-four patients with ULR from TED were submitted to transcutaneous injection of 5 units (0.1 ml) of Botox in one eye only. Patients were divided into two groups: 12 with congestive-stage TED (CG), and 12 with fibrotic-stage TED (FG). Bilateral lid fissure measurements using digital imaging and computer-aided analysis were taken at baseline and at regular intervals 2 weeks, 1 month, 3 months and 6 months after unilateral Botox injection. Mean values taken at different follow-up points were compared for the two groups.


RESULTS
Most patients experienced marked improvement in ULR, with a mean reduction of 3.81 mm in FG and 3.05 mm in CG. The upper eyelid margin reflex distance, fissure height and total area of exposed interpalpebral fissure were significantly smaller during 1 month in CG and during 3 months in FG. Reduction in LF and in the difference between lateral and medial lid fissure measurements was observed in both groups. The treatment lasted significantly longer in FG than in CG.


CONCLUSIONS
A single 5-unit Botox injection improved ULR, reduced LF and produced an adequate lid contour in patients with congestive or fibrotic TED. The effect lasts longer in patients with fibrotic orbitopathy than in patients with congestive orbitopathy.
Oculoplastic and Orbital Diseases Services, Hospital das Clínicas of the University of São Paulo Medical School, São Paulo, Brazil.
P G
PG
Costa
F P
FP
Saraiva
I C
IC
Pereira
M L R
ML
Monteiro
S
S
Matayoshi
D000328:Adult; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D005141:Eyelid Diseases / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005152:Facial Muscles / Q000502:physiology; D005260:Female; D049970:Graves Ophthalmopathy / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D013959:Thyroid Diseases / Q000150:complications
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A